Please visit answersincme.com/WTR860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in hepatology and endocrinology discuss the impact of obesity on liver disease progression, current and emerging GLP-1 receptor agonist therapies, and strategies to optimize clinical outcomes in metabolic dysfunction-associated steatohepatitis (MASH). Upon completion of this activity, participants should be better able to: Identify how obesity impacts metabolic dysfunction–associated steatohepatitis (MASH) progression and liver health; Review current and emerging glucagon-like peptide-1 (GLP-1) receptor agonist (RA)–based therapies for the treatment of MASH; and Outline approaches to optimize patient outcomes in obesity-related liver disease.